Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK
Document type:
Meeting Abstract
Author(s):
Al-Batran, S-E.; Lorenzen, S.; Homann, N.; Thuss-Patience, P. C.; Schenk, M.; Lindig, U.; Kretzschmar, A.; Heuer, V.; Goekkurt, E.; Haag, G. M.; Knorrenschild, J. Riera; Bolling, C.; Hofheinz, R. D.; Siebenhuener, A. R.; Irahara, N.; Kopp, C.; Waberer, L.; Pauligk, C.; Gotze, T. O.; Gaiser, T.